drugset / Trial / NCT03772613
The Randomized OPTIMAL-ACT Trial
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to find the ideal range of the activated clotting time (ACT) during percutaneous coronary intervention (PCI) that is associated with lowering the rate of undesirable medical outcomes
Timeline
- Start
- 2019-02-08
- Primary completion
- 2021-10-25
- Completion
- 2021-10-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Heparin | Other / unclassified | — | — |